RNS Number : 3825O
Versarien PLC
09 February 2021


9 February 2021

Versarien plc

("Versarien" or the "Company")

Graphene Enhanced Mask Update


Versarien plc (AIM: VRS), the advanced materials engineering group, is pleased to provide an update on recent developments with regard to the Company's graphene enhanced face masks.


As reported in the Company's interim results announced on 21 January 2021, the Company's wholly owned Chinese subsidiary, Beijing Versarien Technology Company Limited, has been working with its partner on further developments of the masks.  This included the testing of a prototype second generation graphene enhanced face mask conducted in China at the Analytical and Testing Centre of Capital Regions which showed a 99.92% anti-viral activity rate against the SARS-CoV-2 virus.


In a further development, the Company is pleased to report that, after testing of prototypes of the latest version of the mask, which is a non-valve mask, it has been certified as meeting the FFP3 standard, the highest standard under the European EN149 standard for filtering half face masks.


The FFP3 certification process, included, inter alia, the testing of the packaging, the robustness of the material, its practical performance, total inward leakage, breathing resistance, clogging, compatibility with skin and the carbon dioxide content of the inhalation air.  In order to meet the criteria to be certified as a FFP3 mask, the mask had to pass all the relevant tests, including demonstrating less than 2% inward leakage and the filtering of at least 99% of particulate matter.


The testing, to the European EN149 standard, has been carried out in China by SGS-CSTC Standards Technical Services Co. Ltd a joint venture founded in 1991 between SGS Group, a world leading inspection, verification, testing and certification company, and China Standard Science and Technology Group.  Further information on SGS in China may be found at https://www.sgsgroup.com.cn/en/our-company/about-sgs/sgs-in-brief/sgs-in-china 


Neill Ricketts, CEO of Versarien, commented: "We are delighted that the latest version of our mask has passed the rigorous FFP3 testing process.  Whilst we currently have an FFP2 mask on sale that we believe compares very well with other masks available, being able to offer a non-valve FFP3 mask with anti-viral properties is a significant further step and we intend to bring these masks to the market as soon as possible."





Neill Ricketts, CEO

Chris Leigh, CFO

+44 (0)1242 269 122

SP Angel Corporate Finance (Nominated Adviser and Joint Broker)

Matthew Johnson, Ewan Leggat, Adam Cowl

+44 (0)20 3470 0470

Berenberg (Joint Broker)

Mark Whitmore, Simon Cardron

+44 (0)20 3207 7800

Yellow Jersey (Investor Relations) 

Charles Goodwin

Georgia Colkin

Henry Wilkinson


+44 (0)774 778 8221


Notes to Editors:


Versarien Plc (AIM:VRS), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries.


For further information please see: http://www.versarien.com 


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.